Immune checkpoint inhibitors (ICIs, e.g., antiprogrammed cell death protein 1 [PD-1]) and targeted therapies (e.g., BRAF/MEK inhibitors) have revolutionized treatment for melanoma patients (MPs), but prognostic markers of drug response and disease progression remain elusive. Here, BRAF is linked to melanoma.